Predict your next investment

Medison Pharma company logo
Corporation
BUSINESS PRODUCTS & SERVICES | Advertising, Marketing & PR
medison.co.il

See what CB Insights has to offer

Investments

2

Portfolio Exits

1

Partners & Customers

10

About Medison Pharma

Medison Pharma is a marketing group that represents niche healthcare solutions companies such as Biogen, Amgen, Shire and Ipsen.

Medison Pharma Headquarter Location

HaShiloah St 10 P.O.B 7090

Petah Tikva, 4917002,

Israel

972.3.925.0250

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Medison Pharma Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Medison Pharma Rank

Latest Medison Pharma News

Israeli-Founded Pharma Firm Partners with Dutch Biotech Firm

Jun 8, 2022

Scientist pouring a liquid in an Erlenmeyer flask with a test tube in a laboratory. Israeli-founded global pharmaceutical firm Medison Pharma , announced a multi-regional partnership with Dutch biotechnology company argenx , on Monday to commercialize its efgartigimod drug in 14 countries including Israel. Efgartigimod is approved in the United States for the treatment of adults with generalized myasthenia gravis (gMG), an autoimmune disorder that weakens multiple muscle groups throughout the body, thus impairing motor function. According to the announcement, the drug is also commonly used in Japan for the treatment of adults with gMG who do not have sufficient response to steroids or non-steroidal immunosuppressive therapies (ISTs). The drug will also be commercialized in Poland, Hungary, Slovenia, Czech Republic, Romania, Bulgaria, Lithuania, Croatia, Slovakia, Estonia, Latvia, Greece, and Cyprus, in addition to Israel. Argenx was founded in 2008 and has since developed an “ antibody innovation ecosystem ,” or a pipeline of various immunology solutions to expedite the discovery of novel targets, disease pathways, and differentiated therapeutic antibodies. Founded in 1996 by CEO Meir Jakobsohn, Medison Pharma is one of the largest commercial partners of leading global biotech companies worldwide, providing a comprehensive range of integrated services for biotech companies looking to enter or expand their presence in Israel, Canada and Central Eastern Europe. The firm also focuses on providing patients in international markets access to highly innovative therapies and actively invests in disruptive healthcare technologies rooted in biotech and digital health verticals. “We are on a mission to help patients with severe, rare diseases get faster access to highly innovative therapies, regardless of where they live in the world,” said Jakobsohn. “By partnering with argenx, we provide a force multiplier for this breakthrough therapy, helping to save and improve the lives of patients living with generalized myasthenia gravis.” “We are proud to partner with argenx and help extend their reach to treat patients with severe autoimmune diseases in 14 countries,” said Victor Papamoniodis, VP of International Markets at Medison Pharma. “We look forward to utilizing our unique commercial platform and applying our expertise to facilitate faster access to this novel therapy for patients across all our markets.” Subscribe to NoCamels weekly newsletter and get our top stories

Medison Pharma Investments

2 Investments

Medison Pharma has made 2 investments. Their latest investment was in Keros Therapeutics as part of their Series C on March 3, 2020.

CBI Logo

Medison Pharma Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

3/12/2020

Series C

Keros Therapeutics

$56M

No

3

11/21/2018

Series B

Subscribe to see more

$99M

Subscribe to see more

10

Date

3/12/2020

11/21/2018

Round

Series C

Series B

Company

Keros Therapeutics

Subscribe to see more

Amount

$56M

$99M

New?

No

Subscribe to see more

Co-Investors

Sources

3

10

Medison Pharma Portfolio Exits

1 Portfolio Exit

Medison Pharma has 1 portfolio exit. Their latest portfolio exit was Keros Therapeutics on April 08, 2020.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

4/8/2020

IPO

$99M

4

Date

4/8/2020

Exit

IPO

Companies

Valuation

$99M

Acquirer

Sources

4

Medison Pharma Partners & Customers

10 Partners and customers

Medison Pharma has 10 strategic partners and customers. Medison Pharma recently partnered with Hansa Biopharma on March 3, 2022.

Date

Type

Business Partner

Country

News Snippet

Sources

3/29/2022

Partner

Sweden

Hansa Biopharma and Medison Pharma announce marketing authorization in Israel for Idefirix® (imlifidase) for desensitization treatment of highly sensitized kidney transplant patients

Hansa Biopharma AB , `` Hansa Biopharma AB '' , the pioneer in enzyme technology for rare immunological conditions , and its partner Medison Pharma , a global pharma company focused on providing access to highly innovative therapies to patients in international markets , today announce that the Israeli Ministry of Health has approved Idefirix ® for desensitization treatment of highly sensitized kidney transplant patients in Israel .

1

1/9/2022

Partner

Sweden

Hansa Biopharma provides business update including certain key financials

The commercial partnership with Medison Pharma represents an important milestone for Hansa Biopharma AB as the Company expands access to imlifidase for highly sensitized patients incompatible with a deceased donor .

1

12/7/2021

Licensor

Sweden

Hansa Biopharma and Medison Pharma announce multiregional commercialization partnership for Hansa's desensitization treatment for kidney transplant in Central Eastern Europe and Israel

`` This new commercial partnership with Medison Pharma is an important milestone for Hansa Biopharma AB as it expands access to imlifidase for highly sensitized patients awaiting kidney transplants , '' says Søren Tulstrup , President & CEO of Hansa Biopharma AB .

1

10/21/2021

Partner

Israel

Subscribe to see more

Subscribe to see more

10

3/8/2021

Licensor

Ireland

Subscribe to see more

Subscribe to see more

10

Date

3/29/2022

1/9/2022

12/7/2021

10/21/2021

3/8/2021

Type

Partner

Partner

Licensor

Partner

Licensor

Business Partner

Country

Sweden

Sweden

Sweden

Israel

Ireland

News Snippet

Hansa Biopharma and Medison Pharma announce marketing authorization in Israel for Idefirix® (imlifidase) for desensitization treatment of highly sensitized kidney transplant patients

Hansa Biopharma AB , `` Hansa Biopharma AB '' , the pioneer in enzyme technology for rare immunological conditions , and its partner Medison Pharma , a global pharma company focused on providing access to highly innovative therapies to patients in international markets , today announce that the Israeli Ministry of Health has approved Idefirix ® for desensitization treatment of highly sensitized kidney transplant patients in Israel .

Hansa Biopharma provides business update including certain key financials

The commercial partnership with Medison Pharma represents an important milestone for Hansa Biopharma AB as the Company expands access to imlifidase for highly sensitized patients incompatible with a deceased donor .

Hansa Biopharma and Medison Pharma announce multiregional commercialization partnership for Hansa's desensitization treatment for kidney transplant in Central Eastern Europe and Israel

`` This new commercial partnership with Medison Pharma is an important milestone for Hansa Biopharma AB as it expands access to imlifidase for highly sensitized patients awaiting kidney transplants , '' says Søren Tulstrup , President & CEO of Hansa Biopharma AB .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

1

1

10

10

Medison Pharma Team

1 Team Member

Medison Pharma has 1 team member, including current Founder, Chief Executive Officer, Meir Jakobsohn.

Name

Work History

Title

Status

Meir Jakobsohn

Founder, Chief Executive Officer

Current

Name

Meir Jakobsohn

Work History

Title

Founder, Chief Executive Officer

Status

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.